Lithuania vs Sur: Previously treated cases tested for RR-/MDR-TB
Lithuania
100.0%
in 2024
Sur
62.0%
in 2024
Lithuania rank
1st
Sur rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Lithuania
- Sur
How they compare
Lithuania currently reports 100.0% against 62.0% in Sur, a difference of 38.0%.
That makes Lithuania's figure about 1.6 times Sur's.
The two have swapped places 2 times across 17 shared years of data; in 2005 it was Lithuania ahead.
Lithuania ranks 1st and Sur ranks 1st of 180 countries.
Lithuania has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Lithuania | Sur | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 98.7% | 14.3% | 84.3% | Lithuania |
| 2010s | 100.0% | 53.0% | 47.0% | Lithuania |
| 2020s | 100.0% | 78.4% | 21.6% | Lithuania |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Lithuania or Sur?
- Lithuania, at 100.0% against 62.0% in Sur as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Lithuania and Sur?
- 38.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Sur?
- 17 years are reported by both, from 2005 to 2024.
- How do Lithuania and Sur rank globally for previously treated cases tested for rr-/mdr-tb?
- Lithuania ranks 1st and Sur ranks 1st of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.